Tvardi Therapeutics, Inc. (FRA:69C)

Market Cap	31.35M
Revenue (ttm)	n/a
Net Income	-20.15M
EPS	-2.75
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	2.645
Previous Close	2.785
Day's Range	2.645 - 2.645
52-Week Range	2.625 - 37.000
Beta	n/a
RSI	35.08
Earnings Date	May 29, 2026

About Tvardi Therapeutics

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2017
• Employees: 12
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 69C

Financial Performance

Financial numbers in USD